20cm速递｜科创创新药ETF国泰（589720）涨超3%，机构：中国创新药行业迈向“全球引领”新阶段

Group 1 - The core viewpoint is that China's innovative drug industry is entering a new phase of "global leadership" supported by comprehensive policies, marking a historical turning point for the industry [1] - The industry is transitioning from "generic following" to "original innovation," with an accelerated internationalization process through active business development (BD) transactions [1] - Several companies are beginning to realize commercialization, achieving "self-sustaining" growth, indicating a profitability turning point for the industry [1] Group 2 - The Guotai ETF (589720) focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking a representative index of 30 high-quality companies, primarily in high-growth biotech [1] - Since the "924 market," the Sci-Tech Innovation Drug Index has outperformed major Hong Kong drug indices, with returns of 75% for the Sci-Tech Innovation Drug Index compared to 70% for both the Hong Kong Innovation Drug Index and the Hang Seng Hong Kong Connect Innovation Drug Index during the market rebound from September 24, 2024, to June 30, 2025 [1] - The innovative drug industry is expected to have broad development space and good investment opportunities driven by continuous breakthroughs in international markets, ongoing policy benefits, and steady improvements in the R&D capabilities of Chinese innovative drug companies [1]